Kai-hong Huang

List of Publications by Year
in descending order

22 papers	696 citations	687363 13 h-index	610901 24 g-index
28 all docs	28 docs citations	28 times ranked	1192 citing authors

#	Article	IF	Citations
1	Pancreatic Cancer Epidemiology, Detection, and Management. Gastroenterology Research and Practice, 2016, 2016, 1-10.	1.5	128
2	Co‑delivery of micro<scp>RNA</scp>‑21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. Cancer Science, 2017, 108, 1493-1503.	3.9	101
3	MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells. Theranostics, 2018, 8, 3074-3086.	10.0	68
4	KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK–ERK pathway in pancreatic cancer. International Journal of Cancer, 2018, 142, 2323-2334.	5.1	62
5	MicroRNA hsa-miR-370-3p suppresses the expression and induction of CYP2D6 by facilitating mRNA degradation. Biochemical Pharmacology, 2017, 140, 139-149.	4.4	57
6	Bmi-1-induced miR-27a and miR-155 promote tumor metastasis and chemoresistance by targeting RKIP in gastric cancer. Molecular Cancer, 2020, 19, 109.	19.2	43
7	The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p. Biochemical Pharmacology, 2017, 145, 178-191.	4.4	41
8	Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 463-472.	3.3	40
9	Tumor‑driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL‑8. Cancer Medicine, 2018, 7, 5679-5690.	2.8	34
10	New developments in the early diagnosis of pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2017, 11, 149-156.	3.0	23
11	TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Biochemical Pharmacology, 2021, 189, 114085.	4.4	18
12	Expression of the PTEN/FOXO3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression. Investigational New Drugs, 2020, 38, 321-328.	2.6	17
13	Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor metastasis and chemotherapy resistance. Gastric Cancer, 2016, 19, 392-402.	5.3	15
14	Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer. Biochemical Pharmacology, 2021, 189, 114390.	4.4	14
15	Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. Cancer Medicine, 2020, 9, 2971-2980.	2.8	9
16	Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer. Frontiers in Genetics, 2021, 12, 632803.	2.3	6
17	Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro. Tumor Biology, 2016, 37, 11299-11309.	1.8	5
18	Prognostic and metastasis‑related factors in colorectal neuroendocrine tumors: A cross‑sectional study based on the Surveillance, Epidemiology and End Results. Oncology Letters, 2019, 18, 5129-5138.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Peripheral blood monocytes predict clinical prognosis and support tumor invasiveness through NF-κB-dependent upregulation of Snail in pancreatic cancer. Translational Cancer Research, 2021, 10, 4773-4785.	1.0	3
20	Studies on the distribution and radioimmunoimaging of 99mTc-labeled 5-fluorouracil loaded immunological nanoparticles in tissues and human gastric carcinoma xenografts. Chinese Journal of Clinical Oncology, 2007, 4, 307-312.	0.0	1
21	PEI-PEG as a siRNA genetic vector demonstrating interference in the expression of CD44v6 protein in gastric cancer cells. Clinical Oncology and Cancer Research, 2010, 7, 187-192.	0.1	1
22	In vitro lethal effect of photodynamic therapy on human pancreatic cancer cells and its major influencing factors. Clinical Oncology and Cancer Research, 2011, 8, 155-162.	0.1	1